ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

$1.2 Bn Specialty CROs Market Research, Industry Trends and Global Forecasts, 2035 - 200+ Providers Identified from 1,000+ CROs Based on Service Capabilities and Expertise - ResearchAndMarkets.com

The "Specialty CROs Market Industry Trends and Global Forecasts to 2035 - Distribution by Target Therapeutic Area, Type of Service and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.

The global specialty CROs market valued at USD 1.2 billion in 2025, is anticipated to grow at a lucrative CAGR of 8.6% during the forecast period.

Over the years, the biopharmaceutical industry has undergone a major transformation in its approach towards R&D outsourcing. Specialty contract research organizations (CROs) have become prominent players, addressing limitations often faced with traditional, full-service CROs.

While full-service providers offer a broad range of capabilities, they frequently struggle to tailor their services to the specific needs of small-scale biotech companies and start-ups.In contrast, specialty CROs focus on niche segments, delivering expertise in targeted clinical or preclinical services, while concentrating on a particular disease area such as oncology, heart diseases, metabolic disorders, and central nervous system (CNS) conditions.

Services commonly outsourced to these organizations include pharmacovigilance, target evaluation, formulation development, cell line development, data management, project management, biostatistics and others. Further, specialty CROs are also increasingly adopting strategic models to broaden their service offerings and expand geographically, aiming to better serve the evolving needs of the global biopharmaceutical sector.

Specialty CROS Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the specialty CROs market, focusing on key market segments, including target therapeutic area, type of service and key geographical regions.
  • Market Landscape: A comprehensive evaluation of specialty CROs, based on several relevant parameters, such as geographical location, year of establishment and R&D capabilities.
  • Company Profiles: In-depth profiles of specialty CROs focused on specialized preclinical / clinical service offering and particular therapeutic area, based on overview of the company, service portfolio and recent developments and an informed future outlook.
  • Case Study 1: A detailed discussion of the virtually integrated, cross-functional outsourcing approach implemented by virtual CROs.
  • Case study 2: A detailed discussion of the one-stop-shop approach followed by traditional CROs.

Specialty CROs Market: Key Insights

  • The wealth of services offered by CROs have made them an indispensable platform for drug development.
  • Over 200 speciality CROs were identified after detailed due diligence of more than 1,000 CROs based on the specific capabilities and the range of services they provide.
  • With 26% of the organizations specializing in preclinical services, the service portfolio of these CROs caters to a wide array of client requirements.
  • Toxicology and pharmacology are the most popular preclinical services, with ~14% of the CROs offering the services related to toxicology and pharmacology in their respective portfolios.
  • Nearly 32 companies specialize in test models and medical imaging / biomarker-based analysis.
  • Over 40% of the speciality CROs offered biostatistics related services, followed by speciality CROs offering clinical monitoring and project management services.
  • Notably, medical writing and regulatory management / submission is also frequently outsourced.
  • Though the overall market is dominated by a handful of bigger CROs, the market within the speciality CRO segment is highly fragmented; US continues to remain the primary hub.
  • Newer approaches / untapped opportunity areas are likely to emerge as key growth drivers in the long-term.
  • Notably, as specialty CROs further establish their service portfolios, it is believed that the market is likely to sustain the growth momentum in the coming years.

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

SPECIALTY CROs: FOCUSED ON SERVICES

CROs Focused on Preclinical Service Capabilities

  • BRI Biopharmaceutical Research
  • BTS Research
  • Dorizoe Lifesciencess
  • Customized Services
  • Fluofarma
  • KIYATEC
  • Redoxis
  • Spirovation
  • Velesco Pharmaceutical Services

CROs Focused on Clinical Service Capabilities

  • Almedis
  • Applied Healthcare Resource Management
  • CMX Research
  • MDappsT
  • DZS Clinical Services
  • EthosExcelT
  • ICRC-Weyer
  • Impact Pharmaceutical Services
  • Research Dynamics Consulting
  • SDS Clinical

SPECIALTY CROs: FOCUSED ON THERAPEUTIC AREAS

  • Accelovance
  • MedSource
  • Novella Clinical

Specialty CROs Focused on Cardiovascular / Cardiology

  • Cardialysis
  • IonsGate Preclinical Services

Specialty CROs Focused on Metabolic Disorders

  • Betagenex
  • Physiogenex
  • Profil Institute

Specialty CROs Focused on CNS

  • Biospective
  • RenaSci
  • RxGen

CASE STUDY I: VIRTUAL CROs

  • Frestedt
  • InSymbiosis
  • Osiris Pharma
  • ProjectPharm
  • The Harte Group
  • VxP Pharma

CASE STUDY II: FULL SERVICE CROs

  • Covance
  • Medis Research Group
  • Quintiles
  • Triclinium Clinical Trial Project Management

FUTURE OPPORTUNITIES

  • Chapter Overview
  • The Changing Scenario of Outsourcing
  • Health Economics and Outcomes Research (HEOR) Studies
  • Adaptive Trial Design
  • eClinical Solutions
  • Risk Based Monitoring (RBM)
  • Digital CRO (dCRO)

CONCLUSION

  • A Widening Portfolio of Services Governed by Industry Constraints
  • Closer Working Collaboration is the Key to Success
  • Within Therapeutic Areas, Oncology is the Flagbearer
  • Due to Several Niche Offerings, Specialty CRO Market Remains Fragmented
  • The Market of Specialty CROs is Likely to Sustain the Growth Momentum
  • Untapped Opportunity Areas will Emerge as Key Growth Drivers in the Long-Term
  • Concluding Remarks

INTERVIEW TRANSCRIPTS

  • Chapter Overview
  • Raf Magar, President, CRO and Outcomes Research, AHRM
  • Jeffrey P. Kiplinger, President, Averica Discovery Services

Target Therapeutic Area

  • Oncological Disorders
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Diabetes
  • Others

Type of Service

  • Preclinical Services
  • Clinical Services

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

For more information about this report visit https://www.researchandmarkets.com/r/2o9j6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+0.00 (0.00%)
AAPL  268.47
+0.00 (0.00%)
AMD  233.54
+0.00 (0.00%)
BAC  53.20
+0.00 (0.00%)
GOOG  279.70
+0.00 (0.00%)
META  621.71
+0.00 (0.00%)
MSFT  496.82
+0.00 (0.00%)
NVDA  188.15
+0.00 (0.00%)
ORCL  239.26
+0.00 (0.00%)
TSLA  429.52
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.